Grandmothers Against Poverty and AIDS (GAPA) empowers grandmothers caring for HIV/AIDS-affected families with peer support, income-generating activities. Studies show GAPA members experience higher self-esteem and reduced poverty, stigma in their community.
A study suggests that patients with non-squamous histology achieve statistically significant higher survival when treated with ALIMTA in the second-line setting compared to those with squamous histology. The analysis also identified other predictive factors for potential benefit from treatment, including adenocarcinoma histology and go...
A recent Phase II study evaluating the addition of GEMZAR to standard chemotherapy regimens showed promising results in treating stage II-III breast cancer. The treatment regimen demonstrated a high pathologic complete response rate, with additional benefits for HER-2 positive patients who received trastuzumab. These findings support t...
A Phase III study suggests ALIMTA-carboplatin may deliver less toxicity than GEMZAR-carboplatin, offering comparable quality-of-life benefits and survival data. The combination also appears to benefit from a lower toxicity profile.
A multicenter Phase II study of enzastaurin as a second- or third-line treatment for NSCLC found a median progression-free survival of 1.9 months and an overall survival rate of 46.3% at 12 months. The most common toxicity was fatigue.
Two Lilly studies analyzed data from African-American and Hispanic patients with non-small cell lung cancer (NSCLC), suggesting race may not significantly impact treatment efficacy. The studies provided insight into the safety profiles of ALIMTA and GEMZAR in diverse populations, paving the way for further research.
Lilly Oncology will present data on three oncology agents, ALIMTA, GEMZAR, and enzastaurin, at the 43rd Annual Meeting of the American Society of Clinical Oncology. The company's studies focus on various types of cancer, including non-small cell lung cancer and breast cancer.
New data confirm Relenza's effectiveness in targeting viral replication and reducing complications in patients with influenza B. High concentrations of the drug in the lungs also reduce the risk of resistance development.